论文部分内容阅读
食管腺癌是西方国家中发病率增加最快的恶性肿瘤之一,患者的5年生存率低于20%。以铂类药物为基础的新辅助化疗是治疗晚期食管腺癌的标准方案,虽然新辅助化疗能够延长部分化疗有效病人的生存期,但是仍有许多患者死于肿瘤复发。EGFR(表皮生长因子受体)是肿瘤细胞增殖信号通路中重要的调节因子,参与调控细胞增殖,转移和组织再生。研究发现EGFR高表达和EGFR基因组扩增与直接接受手术治疗的晚期食管腺癌患者预后不良有关,然而,对于接受过新辅助化疗的患者,EGFR的表达水平与其预后的关系仍不清楚。为此,德国的Walch教授等开展了一项研究,旨在探讨接受过以铂类药物为基础的新辅助化疗的晚期食管腺癌患者中,
Esophageal adenocarcinoma is one of the most rapidly increasing malignant tumors in Western countries with a 5-year survival of less than 20%. Neoadjuvant chemotherapy based on platinum drugs is the standard treatment for advanced esophageal adenocarcinoma. Although neoadjuvant chemotherapy can prolong the survival of patients who are effective in some chemotherapy, many patients die of tumor recurrence. EGFR (epidermal growth factor receptor) is an important regulatory factor in tumor cell proliferation signaling pathway, which is involved in the regulation of cell proliferation, metastasis and tissue regeneration. However, the relationship between the expression of EGFR and the prognosis of patients with neoadjuvant chemotherapy remains unclear. To this end, Germany’s Walch Professor conducted a study to explore advanced platinum-based neoadjuvant chemotherapy in patients with advanced esophageal adenocarcinoma,